REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Regenxbio (RGNX) Misses Q3 EPS by 22c, Revenues Beat
November 5, 2019 4:55 PM ESTRegenxbio (NASDAQ: RGNX) reported Q3 EPS of ($0.94), $0.22 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $9.74 million.
Initiation of RGX-314 Phase IIb trial for wet AMD and IND filing for Phase II trial in diabetic retinopathy now expected in Q1 2020 as a result of partial clinical hold following FDA notification related to certain commercial, third-party surgical devices; matter is not related to RGX-314 gene therapy candidatePositive interim update from RGX-314 Phase I/IIa trial for wet AMD presented in October at... More